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INTRODUCTION
The interplay of various hormones originating from the
hypothalamic-pituitary-gonadal axis regulates the develop-
ment and maintenance of mammalian reproduction. The
central regulators in this system are the pituitary
gonadotropins, i.e., leutenizing hormone (LH) and follicle-
stimulating hormone (FSH). The synthesis and secretion
of both of these hormones are controlled by a combina-
tion of hypothalamic gonadotropin-releasing hormone
(GnRH) and the gonadal steroids. The gonadal steroids
exert feedback actions on the brain to attenuate the
release of GnRH and on the anterior pituitary gland to
inhibit the secretion of LH and FSH. In recent years,
several hypophysiotropic protein factors that can regulate
the release of FSH by pituitary cells have been identified
in mammalian gonads. These include activin (1, 2), which
stimulates FSH release, and inhibin (3-6) and follistatin
(FS) (7), which inhibit FSH release. These protein factors
have added a new dimension to the complexity of this
system.
Although functionally antagonistic, activin and inhibin
are structurally related ; inhibin is a heterodimer com-
posed of an α-subunit linked by disulfide bonds to one of
the related β-subunits, whereas activin is a dimer com-
posed of the inhibin β-subunits (8-13). Five β-subunits
have been reported : βA, βB, βC (14), βD (15) and βE
(16), whereas only a single α-subunit has been identified.
There is an extensive array of possible dimers ; inhibin A
(αbA), inhibin B (αbB) (5, 6), activin A (βAβA)(1), activin
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AB (βAβB) (2) and activin B (βBβB) (17) have been
isolated as dimeric proteins. DNA sequence analyses
showed that all of the subunits are initially synthesized as
large precursor proteins with the mature subunits
residing at the COOH-terminal regions of the several clus-
ters of multiple basic residues which can serve as
potential proteolytic processing sites (Fig.1). The sizes of
the mature, most abundant forms of each subunit are 18
kDa for the α-subunit and 14 kDa for the βA-and βB-
subunits. Thus, depending on the combination of the gene
products, protein molecules having quite different biologi-
cal activities could be derived from a limited number of
genes.
The finding of a homodimeric form of a β-subunit is
noteworthy in view of the fact that the members of the
transforming growth factor-β (TGF-β) superfamily are all
homodimers. Structural studies have shown that these
proteins constitute the TGF-β superfamily with diverse
regulatory effects on the growth and differentiation of
numerous cell types. These findings prompted us to
elucidate the full spectrum of actions of activin and inhibin
apart from their effects on FSH secretion. There is in-
creasing evidence from various areas of study that activin
has multiple functions in a wide variety of biological
systems, e.g., the regulation of the secretion of anterior
pituitary hormones such as growth hormone, prolactin
and corticotropin (1,18-22), the induction of erythropoiesis
(23-26), the modulation of ovarian and testicular cell
functions (27-31), the promotion of survival of nerve cells
(32,33), the initiation of early embryonic development of
Xenopus (34-40), the stimulation of insulin secretion (41),
and the enhancement of bone formation (42-44). In view of
the wide spectrum of bioactivities exerted by activin, it is
not surprising that the mRNA encoding β-subunits is
found in a multitude of diverse tissues, including the
gonads, pituitary, placenta, brain, spleen, heart, bone mar-
row and others (45). Activin is a growth and differentiation
factor that is produced by and exert effects on a broad
range of cells and tissues (Fig.2).
In contrast, inhibin is a functional antagonist to activin
in some systems. This antagonism was first observed with
regard to FSH secretion by pituitary cells, but has also
been documented for a number of other responses. There
are, however, many activin responses that do not appear
to be regulated by inhibin ; inhibin-independent effects
have been described.
Despite the various effects of members of the TGF-β
superfamily on cell phenotype and physiology, until
recently very little was known about the structures of their
receptors or the signaling mechanisms. An activin recep-
tor was recently cloned from the mouse
pituitary tumor-derived cell line AtT 20 (46).
The receptor sequence predicted a transmem-
brane serine/threonine-specific protein kinase.
This result was unexpected, because at that
time all known cytokine receptor kinases were
tyrosine-specific. With the use of the activin
receptor cDNA as a low-stringency hybridiza-
tion probe or to direct the construction of
degenerate oligonucleotides for polymerase
chain reaction (PCR), a number of additional
receptor serine kinases have been cloned.
These are divided into two classes, called
type I and type II receptors, both of which
contain a serine/threonine kinase domain in
their intracellular domains. Activin and other
members of the TGF-β superfamily interact
with both types of receptors. Activin and
TGF-β can bind their individual type II
receptor but fail to bind the type I receptor in
the absence of the type II receptor. The
ligand-bound type II receptor can associate
with the type I receptor. This ligand-induced
heteromerization between the type I and type
II receptors results in the ligand signal
transduction (Fig.3). In the current model, the
function of the type II receptor is confined to
ligand binding, type I receptor recruitment
and transphosphorylation, whereas the type I
receptor is the signaling unit in the complex
(reviewed in Ref.47). Furthermore, intra-
cellular mediators such as the Smad's have
been identified and used for the clarification of
signaling mechanisms for activin and otherFig. 2. Multiple functions of activin.
Fig. 1. Structures of inhibin and activin. The multiple arrangement of gene products
from the α, βA and βB subunit precursors through disulfide bridging yields FSH
releasers (activin) and suppressors (inhibin).
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members of the TGF-β superfamily.
Additionally, in 1987, a new class of gonadal protein
factor, named FSH-suppressing protein (FSP) or FS, was
identified in a side fraction derived from the purification of
bovine and porcine ovarian inhibins and activins (7, 48).
FS was characterized initially by its ability to suppress
pituitary cellular FSH secretion in vitro . The action of FS
appears to be similar to that of inhibin, but it is structur-
ally quite different. FS is a single-chain protein that occurs
in 31-to 39-kDa molecular mass forms, all of which have
similar amino acid compositions and identical amino-
terminal amino acid sequences. In a recent study, we
purified an activin-binding protein which was specific to
and had a high affinity for activin, from rat ovary (49) and
bovine pituitary (50), and we demonstrated that it was
identical to FS. Interest in the biological significance of FS
had diminished, because of its weak inhibitory activity
compared with that of inhibin. However, our finding that
FS is an activin-binding protein sheds new light on the
understanding of its physiological role ; FS may partici-
pate in the regulation of the multiple actions of activin.
Indeed, FS mRNA transcripts have been detected in a
wide variety of tissues, which may indicate that FS, like
activin, has tissue-specific effects or that FS has a univer-
sal action on different cell types. The ability of FS to bind
the preiotropic growth and differentiation factor activin
and thereby neutralize activin action makes this glycopro-
tein a potentially important regulatory factor, capable of
modulating autocrine and paracrine functions and the
processes of differentiation and development. In this
review, we describe the biochemical properties of FS and
the biological implications of FS-activin interaction in a
local regulatory system.
MOLECULAR HETEROGENEITY OF FOLLISTATIN
FS was originally detected as a mixture containing
several bioactive polypeptides in bovine and porcine folli-
cular fluids. Thereafter, the FS gene product processing
was investigated and it was revealed that alternative
splicing generated two types of FS precursor (51, 52). One
is a pre-FS and the other its COOH-terminal 27-amino acid
truncated homologue. The corresponding mature FS
isoforms comprise 315 (FS-315) and 288 (FS-288) amino
acids, respectively.
We have established a conventional procedure for
purifying FS proteins from mammalian and amphibian
sources. To date, we have purified FS from rat ovary (49),
porcine (17) and human (53) follicular fluids, bovine pitui-
tary (50) and Xenopus XTC cell-culture medium (54).
Every preparation demonstrated multiple bands at a 32-38
kDa molecular mass range when subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under non-reducing conditions. After reduction, all
these bands migrated characteristically at a higher mo-
lecular mass range (40-45 kDa). In order to
determine the exact chemical and biological
properties of each FS isoform, we isolated
each one from porcine follicular fluid and
found that there are at least six (and probably
more) FS molecular forms, which resulted
from truncation of the COOH-terminal region
and/or the presence of N-linked carbohydrate
chains (Fig.4) (55). The six FS isoforms can
be divided into three groups, according to
the extent of truncation ; i.e., full-length core
proteins with 315 amino acids (FS-315),
those with 303 amino acids (FS-303), and a
COOH-terminal truncated protein with 288
amino acids (FS-288). Characteristically, both
FS-315 and FS-303, but not FS-288, contain a
highly acidic carboxyl-terminal extension. The
FS-303 molecular form is a major component
of FS from mammalian sources. Interestingly,
unlike mammalian FSs, the core protein of
Xenopus FS may be of a single type (54),
and its heterogeneity may be attributable to
the number of carbohydrate chain moieties,
since the N-glycanase treatment of the
Xenopus preparation resulted in convergence
of the multiple bands on SDS-PAGE. It has yet
to be established as to which isoform group
the Xenopus FS produced by XTC cells
belongs. All six of the molecular species of
FS we have isolated demonstrated almost
identical activin-binding activity (Kd=540-680
pM). The presence of various forms of FS may
Fig. 3. A general model for the initiation of signaling by the activin receptor.
Receptor II is the primary activin receptor and is a constitutively active serine/
threonine kinase that recruits receptor I by means of bound activin. The subsequent
phosphorylation of receptor I by receptor II allows the receptor I kinase to
propagate the signal to downstream substrates.
Fig. 4. Structures of six isoforms of follistatin (FS) from porcine follicular fluid.
CHO : N-linked carbohydrate chain.
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be physiologically significant in the regulation of the many
actions of activin.
TISSUE LOCALIZATION OF FOLLISTAIN
We studied the distribution of FS in rat tissues using
immunohistochemistry (56) with a polyclonal antibody
directed against an FS peptide (residues 123-134) as a
specific immunological probe. In addition to the ovary and
testis, the antiserum bound to almost all of the tissues
tested, i.e., the pituitary, oviduct, uterus, kidney, adrenal
gland, liver, spleen and brain cortex. In the testis, a
unique immunostaining pattern was obtained with intense
and specific FS immunoreactivity evident in spermato-
genic cells. Interestingly, the predominant staining was in
the spermatocytes and spermatid nuclei, but no immune
reaction was observed in spermatogonia or spermatozoa.
To our knowledge, no information has been obtained
regarding how FS gets into the cell nucleus. The pituitary
gland also demonstrated a characteristic staining profile.
The stained spots were scattered sporadically over the
anterior lobe, indicating that a specific group of anterior
pituitary cells, but not all, synthesize FS. The results of
our recent double immunostaining studies suggested that
the cells stained with FS antibodies may be somatotrophs
(57). This staining profile coincided with the distribution
profile of FS mRNA determined using Northern and S 1-
nuclease analyses (58). Our observations clearly indicate
that FS protein is ubiquitous in tissues. A similar broad
tissue localization has also been demonstrated for
inhibin β-subunit mRNA expression. Taken together,
these findings lead us to suggest that FS, in view of its
activin-binding activity, can regulate various activin
actions in many tissues.
MODULATION OF ACTIVIN ACTIONS BY FOLLISTAIN
The widespread tissue distributions of activin and FS
imply, but do not demonstrate conclusively, that both
factors are synthesized locally and that FS regulates the
physiological actions of activin in a paracrine or autocrine
manner. Several lines of indirect evidence suggest that the
biological activities of activin are neutralized by its binding
to FS. In rat granulosa cell cultures, FS (50 ng/ml)
negated the stimulatory effects of activin (30 ng/ml),
including the expression of FSH and LH receptors
and inhibin and progesterone production (Fig.5) (59).
A neutralizing effect of FS on activin activity was
demonstrated in the mouse Friend cell (erythroleukemia
cell) bioassay. When cellular differentiation was induced
by 80 ng/ml activin, an inhibitory neutralizing effect of FS
on erythropoiesis in vivo was observed. The continuous
intraperitoneal administration of FS to normal mice
resulted in a decrease of the erythroid progenitors BFU-E
and CFU-E in the bone marrow and spleen (60).
This supports the hypothesis that endogenous activin
participates in murine erythropoiesis, a process in which
FS exerts a regulatory function. In amphibian systems,
activin appears to be responsible for mesodermal
induction, which was also found to be inhibited by FS in a
dose-dependent manner in the Xenopus animal cap assay.
The coincubation of a constant amount of activin with
increasing concentrations of FS prevented mesodermal
tissue formation : a roughly 3-fold excess of FS (on a
weight basis) was needed to abolish the effect of activin
(61). This also implies that there is a physiological
interaction between activin and FS.
COMPLEX FORMATION BETWEEN ACTIVIN
AND FOLLISTAIN
The ability of FS to bioneutralize the activities of activin
in various assay systems suggests that there is a stoi-
chiometric relationship between FS and activin. We
therefore investigated whether activin binds to FS to form
a biologically inactive complex in vivo (17). Porcine follicu-
lar fluid was collected on ice by aspiration from ovaries of
various sizes and subjected directly to gel filtration. The
immunoblotting analysis of the resulting fractions indi-
cated that more than enough FS exists in follicular fluid
to generate an activin-FS complex. The absence of free
activin was confirmed by the finding that no FSH-release
stimulating activity was detected in any fraction. Next, the
activin-FS complex was purified by successive steps of
affinity chromatography on dextran sulfate-Sepharose and
fast protein liquid chromatography (FPLC) gel permea-
tion on a Superose 12 HR column. This procedure exploits
the high affinity of FS and its complex for sulfated
polysaccharides. The complex thus obtained was sub-
jected to reverse-phase high-performance liquid chroma-
tography (HPLC), which caused it to dissociate and yield
its components, activin and FS. Interestingly, three
isoforms of activins, A, AB and B, were found to be
Fig. 5. Effect of FS on activin-stimulated human chorionic
gonadotropin (hCG)/LH receptor expression (A) and progesterone
production (B) by rat granulosa cells. Granulosa cells (1 x 105
cells/well) obtained from diethylstilbestrol-treated rats were
cultured for 72 h in the presence of FSH (30 ng/ml) without (○) or
with (●) activin (30 ng/ml).
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present as complexes with FS in the follicular fluid. It is
also noteworthy that the biological activity of activin B was
significantly lower than those of activins A and AB in
various assay systems, such as the stimulation of FSH
secretion, the induction of erythrodifferentiation and the
potentiation of gonadotropin receptor expression on
ovarian cells, whereas activin B was a potent inducer of
Xenopus mesoderm. Activin B may therefore play a
specific role in early embryonic development. These
results indicate that mammalian ovarian cells, probably
granulosa cells, synthesize and secrete three activin
isoforms and FS, which easily generate an inert complex
in follicular fluid. Accordingly, to establish the precise
physiological significance of the interplay between FS and
activin in the ovary, it is important to identify the changes
that the components of the complex undergo in relation to
the development of the ovary or during the reproductive
cycle.
ACTIVIN BINDING CAPACITY OF FOLLISTAIN
Although the relationship between activin and FS has
not been characterized fully, there appears to be a
stoichiometric interaction between them. We examined
their interaction using gel permeation FPLC with two
Superose 12 HR columns connected in tandem. The
amounts of the proteins produced were calculated from
the amino acid composition analysis results. When activin
and FS were premixed in a 1 : 2 molar ratio and subjected
to FPLC, a single activin-FS complex peak was observed.
Neither free activin nor free FS peaks were detected.
Even when increasing amounts of FS were added, the
complex peak remained unchanged and a free FS peak
emerged (Fig.6), which indicates that one mole of activin
bound to two moles of FS to form an inactive large
molecular weight complex, and that activin therefore has
two binding sites for FS. A 1 : 1 molar mixture of activin
and FS showed significant FSH-release stimulatory activ-
ity (about 40% of the initial activin activity remained),
whereas no such activity was detected in a 1 : 2 molar
mixture (containing a 2-fold molar excess of FS). This
stoichiometric relationship between FS and activin closely
reflects the antagonistic effect of FS on the activin actions
described above. In studies of the inhibitory effect of FS
on activin action, at least two moles of FS were needed to
neutralize the bioactivity of one mole of activin. This
raised the question of whether inhibin can also bind to FS,
because the inhibin molecule contains a β-subunit derived
from activin. Therefore, we used the gel permeation FPLC
procedure to determine the capacity of inhibin binding to
FS. When a 1 : 1 molar mixture of inhibin and FS was gel-
filtered, the elution peak shifted forward and the forma-
tion of a large molecular complex was observed. A 2-fold
molar excess of FS to inhibin caused no change in the
height of the complex peak, which indicates that inhibin
bound to FS to form a 1 : 1 molar complex. These results
demonstrate that activin has two binding sites (whereas
inhibin has only one) for FS, and imply that FS binds to
both through the common β-subunit.
This explanation of the activin and inhibin FS-binding
capacities is consistent with the results obtained by
Shimonaka et al. (62). However, these studies give no
information about the affinity of inhibition for FS com-
pared with that for activin. Therefore, we tested the
abilities of inhibin and activin to displace 125I-activin bound
to FS ; activin competed for binding with an ED50 of 20 ng/
ml, whereas inhibin was at least 1,000-fold less potent in
this respect (ED50 of 24 μg/ml). This association of inhibin
with FS may not lead to the neutralization of the activity of
either inhibin or FS. Further studies are needed to
elucidate the physiological implications of the interaction
between inhibin and FS.
Another binding protein for inhibin and activin, α2-
macroglobulin (α2M), found in human serum and follicu-
lar fluids was recently identified (63, 64). To test its ability
to bind activin in human serum, SDS-PAGE under non-
reducing conditions of human serum was performed
using 3.6% gels, and the proteins were transferred to
Immunobilon membranes, which were incubated with125I-
activin and subjected to autoradiography. The major α2
(α2M) M band was observed at 370 kDa, which indicated
that α2M may be the primary activin-binding protein in
serum. However, the affinity of activin for α2M is much
lower than that for FS, since typical stoichiometric binding
Fig. 6. Complex formation between activin and FS. Activin, 5 μg,
plus FS,6.6 μg (molar ratio : 1 : 1) (A), activin, 5 μg, plus FS 13.2 μg
(molar ratio : 1 : 2) (B) and activin, 5 μg, plus FS, 19.8 μg
(molar ratio : 1 : 3) (C) were separately incubated in 20 mM Tris/
HCl (pH 7.3) containing 0.1% CHAPS and 1 M NaCl, and each
solution was applied to tandemly connected FPLC Superose 12 HR
columns.
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was not observed in the gel filtration experiments. In
addition, several other bands, including some at around
500 kDa and 180 kDa, were also detected on the blots.
Although these serum proteins that are capable of binding
activin and probably inhibin have not been identified, they
may serve as binding proteins for activin, inhibin and
possibly other factors as well as α2M to protect these
molecules from proteolytic degradation and/or affect their
clearance from the bloodstream.
AFFINITY OF FOLLISTAIN FOR HEPARAN
SULFATE OF PROTEOGLYCANS
In the course of an FS purification study, we noticed
that it possessed a unique and strong affinity for sulfated
polysaccharides, such as dextran sulfate, heparin and sul-
fated cellulose. It was recently proposed that the binding
of basic fibroblast growth factor (FGF) to its receptor
requires prior binding to the heparan sulfate side chains
of proteoglycans or heparin(65). We therefore attempted
to ascertain the physiological significance of FS-sulfated
polysaccharide interactions in regulating activin signal
transduction. Rat granulosa cells cultured in serum-free
medium were incubated with various concentrations of
FS, and the amounts of cell-bound FS were determined by
adding 125I-activin and counting the specifically bound
radioactivity ; this yielded a typical ligand saturation curve
with an apparent Kd of 5 nM. Heparin and heparan sulfate,
but not chondroitin, keratan or dermatan sulfate com-
peted strongly for this binding. When granulosa cells
were treated with various glycosaminoglycan-degrading
enzymes before or after adding FS to the cultures,
heparinase and heparitinase treatment resulted in signifi-
cant suppression of the binding. These results show that
FS has a high affinity for the heparan sulfate side chains of
granulosa cell surface proteoglycans (66).
As discussed above, our FS preparation contains at least
six isoforms, which result from truncation at the COOH-
terminal region and/or the presence of carbohydrate
chains. Interestingly, the affinity for the heparan sulfate
chains was found to differ quite markedly depending on
the sequence of core proteins(55). The COOH-terminal
truncated form (FS-288) showed a very high affinity for
the granulosa cells, with a Kd of 2 nM. In contrast, the full-
length form (FS-315) showed no affinity, whereas the
midsized isoforms (FS-303) showed moderate affinity
(Fig.7). The carbohydrate chains did not appear to affect
their affinity for the cell surface. The association of the
short and midsized FS isoforms with the cell was
abolished by adding heparan sulfate or heparin. High
concentrations of the sulfated polysaccharides (>10 μg/
ml) had no effect on the interaction between activin and
FS. To obtain direct evidence of FS binding to heparan
sulfate, we carried out heparan sulfate-Sepharose affinity
chromatography. Almost all of the short isoform (FS-288)
applied bound to a heparan sulfate-Sepharose column,
whereas the full-length isoform (FS-315) was recovered
quantitatively in the breakthrough fraction, indicating that
it had no affinity for this column. These results clearly
indicate that the amino acid sequence of the COOH-
terminal is important for FS binding to the heparan sulfate
chains of cell surface proteoglycans.
The sequence dependence of FS isoforms on its cellular
association was also confirmed by determining the tran-
sient expression of FS cDNA in COS cells (55). Cells
transfected with the FS-288 cDNA secreted FS-288, which
bound to the COS cells themselves, whereas cells trans-
fected with the FS-315 construct produced the FS-315
protein, which did not bind to the cells. This result shows
that the short form of FS (FS-288) expressed and secreted
by COS cells can bind to the cell surface with a much
higher affinity than that of the long form (FS-315).
The biological response first associated with FS was
inhibition of activin-induced FSH secretion from cultured
rat pituitary cells. To determine whether this inhibitory
activity is affected differentially by the various FS iso-
forms, the potencies of the short, midsized and long FS
forms were compared in this system in vitro . The COOH-
terminal truncated FS (FS-288) was more potent than FS-
303 and FS-315. There was a 5-fold difference between the
inhibitory effects of FS-288 (ED50=2 ng/ml) and FS-303
(ED50=10 ng/ml), and a 2-fold difference between those of
FS-303 and FS-315 (ED50=20 ng/ml), results which are
consistent with the differences in the binding affinities of
these forms to cell surfaces (55). Moreover, a recent
study demonstrated that the in vivo FSH suppressant
activity of recombinant FS-288 in ovariectomized rats was
greater and longer-lasting than that of inhibin A, which
suggests that the COOH-terminal region of FS is impor-
tant for inhibiting the FSH-releasing activity of activin and
probably for exerting other bioneutralizing effects on the
various actions of activin (67). Proteoglycans similar to
those on ovarian granulosa cells may also be present in
the pituitary, and various FS isoforms found locally
therein may be bound by them.
INTERFERENCE BY FOLLISTATIN WITH
ACTIVIN BINDING TO ACTIVIN RECEPTORS
Activin receptor mRNAs have been reported to be
Fig. 7. The cell-adhesiveness of FS isoforms to granulosa cells.
○ : FS-288, △ : FS-288-1 CHO, ● : FS-303, ▲ : FS-303-1 CHO,
■ : FS-303-2 CHO, x : FS-315-1 CHO
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distributed in the rat pituitary (68), but the receptor pro-
tein in the pituitary has yet to be identified. We attempted
to analyze the pituitary activin receptor by affinity cross-
linking 125I-activin A to rat pituitary cells using the bifunc-
tional chemical cross-linker DSS (69). Very faint, but
definite, cross-linked bands of 80 and 100 kDa were
observed (Fig.8), which corresponded well with those of
types I and II activin receptors coexpressed transiently in
COS-7 cells (Fig.8). The binding of labeled activin to both
types I and II activin receptors was abolished in the
presence of excess FS-288 or FS-315 (Fig.8). These find-
ings indicate that the activin-FS complex cannot bind to
activin receptors and would account for the inhibitory
effect of FS on the activin-induced stimulation of FSH
secretion by pituitary cells. De Winter et al . recently
demonstrated that the preincubation of radioiodinated
activin A with FS abolished the activin binding to type II
activin receptors and consequently, its binding to type I
activin receptors, and they proposed that FS can neutral-
ize activin bioactivity by interfering with activin binding to
type II activin receptors (70). Our affinity cross-linking
experiments also showed inhibition by FS of activin
binding to its receptors on rat pituitary cells. This result
can be explained by the hypothesis that FS masks the as
yet unidentified receptor binding domain of the activin
molecule, resulting in the failure of activin to transduce its
signal in responsive cells.
ASSOCIATION OF FOLLISTAIN WITH RAT
PITUITARY CELL SURFACES
Although the formation of activin-receptor complexes
was prevented by adding FS, a broad band with a
molecular mass ranging from 45 to 65 kDa was visible
after treatment with either FS-288 or FS-315 (Fig.8). This
band with a low molecular mass was not related to activin
receptors, because it was also yielded by COS-7 cells that
were not transfected with activin receptor DNAs (Fig.8)
and the labeling of this band was completely inhibited by
incubation with heparan sulfate (Fig.8) and with excess
unlabeled activin, indicating that labeled activin stays on
the cell surfaces via FS bound to the heparan sulfate side
chains of proteoglycans. It should be noted that FS-288
yielded a much more intense band than that yielded
by FS-315 (Fig.8), which was consistent with our
above-mentioned finding that FS-288 showed much higher
affinity than FS-315 for heparan sulfate proteoglycans on
rat ovarian granulosa cells (55). To test this finding
applied to pituitary cells, rat pituitary cells were incubated
with various concentrations of radioiodinated FS. As
expected, FS-288 showed a quite high affinity for the
pituitary cells, whereas the affinity of FS-315 was low.
The association of FS with the cells was completely
suppressed by excess heparan sulfate or heparin,
indicating that FS-288 binds to heparan sulfate on pituitary
cell surfaces.
It is well documented that the interaction between FGF
and heparin-like molecules in the extracellular matrix is
important for various biological functions, such as the
protection of this factor against proteolytic degradation
and its concentration on cell surfaces (65). The role of
heparin-like molecules in signal transduction of FGF is
noteworthy : the binding of basic FGF (bFGF) to its
receptor requires prior binding either to the heparan
sulfate side chains of cell-surface glycosaminoglycan or
to free heparin to present the ligand to the receptor.
De Winter et al . attempted to determine whether cell
surface-bound FS-288 presents activin A to the activin
receptors on human erythroleukemic K 562 cells, and
they found that FS-288 and the activin A-type IIA activin
receptor complex were not coprecipitated by an anti-type
IIA activin receptor antibody (70), suggesting that, unlike
bFGF, cell surface-associated FS cannot present ligands to
signaling receptors. Judging from these
results, FS appears to be nothing more
than a negative regulator for activin,
and its function is to form an inactive
complex with activin to neutralize the
activity of activin.
FATE OF ACTIVIN ASSOCIATED
WITH FOLLISTATIN ON CELL
SURFACES
To investigate the behavior of cell
surface-associated activin via FS, we
examined the binding of activin to FS
associated with pituitary cell surfaces
(69). In the presence of various con-
centrations of FS-288 or FS-315, rat
pituitary cells were incubated with
increasing amounts of 125I-activin A
(0-100 ng/ml ) , and the cell-bound
radioactivities (activin-FS complex)
were then determined (Fig.9). The
binding activity of activin A alone
was difficult to detect, probably due
Fig. 8. Inhibitory effects of FS on 125I-activin A binding to activin receptors on pituitary cells
and COS-7 cells transfected with activin receptor cDNAs. A, rat pituitary cells (5 x 105cells)
cultured in 24-well plates were incubated with 125I-activin A (40 ng/ml) in the absence (a) or
presence (b) of unlabeled activin A (400 ng/ml), and in the presence of FS-288 (200 ng/ml)
(c) FS-315 (200 ng/ml) (d), FS-288 (200 ng/ml) and heparan sulfate (10 μg/ml) (e), or
FS-315 (200 ng/ml) and heparan sulfate (10 μg/ml) (f), cross-linked with DSS, and analyzed
by SDS-PAGE (8% gels). B, COS-7 cells cultured in 6-well plates (2×105 cells) and transfected
with type IA and type IIA activin receptor cDNAs were incubated with 125I-activin A (40 ng/
ml) A in the absence (a) or presence (b) of activin A (400 ng/ml), or porcine FS (200 ng/ml)
(c), cross-linked with DSS, and analyzed by SDS-PAGE (7.5% gels). Untransfected COS-7
cells were also analyzed under the same conditions in the absence (d) or presence (e) of
porcine FS (200 ng/ml) or porcine FS (200 ng/ml) and heparan sulfate (10 μg/ml) (f).
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to the very small number of activin receptors on
pituitary cells. However, as expected, FS-288 markedly
increased the affinity of activin A for cell surfaces, in a
dose-dependent manner, whereas FS-315 did not enhance
the activin A binding to cell surfaces. These results
suggest that activin A can adhere strongly to cells by
forming a complex with FS-288 on the cell surfaces. Next,
we followed the behavior of the cell-associated activin-FS
complex and found that it was degraded endocytotically.
Rat pituitary cells were incubated with radioiodinated
activin A (40 ng/ml) in the presence of increasing
concentrations of FS-288 or FS-315 for various incubation
periods, after which the radioactivities recovered from the
trichloroacetic acid (TCA)-soluble fractions (degraded
activin) of the incubation media were determined using a
γ-spectrometer. As shown in Fig.10, FS-288 stimulated
the activin A degradation significantly time- and dose-
dependently to a greater extent than did FS-315. This
stimulatory effect of FS-288 was abolished by adding
heparin or heparan sulfate to the culture medium. This
result reflects the cell-surface adhesiveness of the
complex : the more strongly the activin A-FS-288 complex
binds to cell-surface heparan sulfate, the more easily it is
degraded. Moreover, this degradation was dependent on
the number of pituitary cells : increasing their number
stimulated the degradation of activin A bound to the cell
surfaces via FS. These degradation data were obtained by
monitoring the degradation of 125I-activin. SDS-PAGE and
gel filtration of the complex samples demonstrated that
the FS component of the activin-FS complex was also
degraded.
ENDOCYTOTIC DEGRADATION OF ACTIVIN
A IN LYSOSOMES
The degradation of cell-bound activin and/or FS by
pituitary cells led us to hypothesize that endocytotic
internalization occurs in the cells and the resulting
endocytotic vesicles ultimately fuse with lysosomes, after
which most of the vesicle contents are
rapidly broken down. To explore this idea,
we examined the effects of various types of
lysosomal enzyme inhibitor on activin A
degradation in rat pituitary cells (69). The
results are summarized in Table 1. The
lysosomal enzyme inhibitors reduced the
degradation significantly, but the serine
protease inhibitor aprotinin had no effect.
The addition of chloroquine, which in-
creases the pH inside lysosomes, to intact
cultured cells inhibited the activin A
breakdown markedly. Both heparin and
heparan sulfate significantly suppressed the
activin degradation, strongly suggesting
that the degradation does not occur until FS
binds to the pituitary cells. The almost
complete inhibition of the degradation by
monensin indicated that the endocytotic
process is essential for the degradative
process.
Autoradiographic experiments using ra-
dioiodinated activin A were also performed
(Fig.11). Pituitary cells were incubated with
125I-activin A at 37℃ in the presence or
absence of FS, heparan sulfate and
chloroquine for 12 h, and the cells were
washed with acid/salt buffer to strip
125I-activin A from their surfaces and then
autoradiographed. FS-288 accelerated the
uptake of activin A by pituitary cells
markedly, and to a greater extent than
did FS-315. Heparan sulfate significantly
suppressed the uptake, a result which
agreed well with the degradation data
described above. The coincubation with
chloroquine inhibited the degradation of
activin A taken up by the cells, probably
in the lysosomes, resulting in activin A
accumulation within the cells. Microscopic
Fig. 10. Effect of FS on endocytotic degradation of 125I-activin A by pituitary cells.
Rat pituitary cells cultured in 96-well plates (8 x 104 cells/well) were incubated with
40 ng/ml 125I-activin A in the presence of various concentrations of FS-288(A) or
FS-315 (B) at 37℃. The medium was collected at the indicated time points and
subjected to trichloroacetic acid treatment. The radioactivity of the trichloroacetic
acid-soluble fraction (degraded 125I-activin A) was determined in a γ-counter. The
concentrations of FS added were 0 (●), 40 (◆), 120 (■), and 400 (▲) ng/ml. The
results are expressed as means±S.D. from triplicate experiments.
Fig. 9. Effect of FS on the binding of 125I-activin A to pituitary cells. Rat pituitary
cells cultured in 96-well plates (8 x 104 cells/well) were incubated with increasing
concentrations of 125I-activin A (0-100 ng/ml) in the presence of various concentra-
tions of FS-288 (A) or FS-315 (B) at 37℃. After a 2 h incubation, specific binding
was determined. The concentrations of FS added were 0(●), 25(◆), 100(■), and
400 (▲) ng/ml. The results are expressed as means ±S.D. from triplicate
experiments.
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observations supported our hypothesis that activin A
bound to pituitary cell surfaces via FS-288 becomes
internalized and packaged into endocytic vesicles, which
fuse with lysosomes, followed by proteolytic degradation
of their contents.
The number of growth factors and cytokines found to
bind to heparin and heparan sulfate is steadily increasing ;
these include FGF, granulocyte-macrophage colony
stimulating factor, interleukin-3, pleiotrophin, hepatocyte
growth factor, vascular endothelial growth factor and
midkine, among others. On the basis of our results
described above, we speculated that, like the activin A-FS-
288 complex, these growth factors bind to cell-surface
heparan sulfate proteoglycans, then become internalized
and eventually are degraded in lysosomes. Indeed, we
found that 125I-bFGF bound to rat cultured pituitary cells in
a dose-dependent manner and that its intracellular
degradation was time-dependent. It is therefore conceiv-
able that such endocytotic degradation of growth factors
is a common mechanism for eliminating signaling
molecules from cell surfaces.
SUPPRESSION OF FSH SECRETION-INHIBITING
ACTIVITY OF FOLLISTAIN BY HEPARAN SULFATE
FS was originally identified as an inhibitor of FSH
secretion by cultured pituitary cells, but its potency was
only 10-30% of that of inhibin (7,48). The mechanism by
which FS acts is unclear, but it has been suggested that it
binds to endogenous activin and neutralizes activin-
stimulated FSH secretion. In an attempt to elucidate how
the interaction between FS and proteoglycans participates
in the FSH-suppressing action of FS, we examined the
effect of heparan sulfate on the inhibitory activity of FS on
rat pituitary cells(69). Dose-response curves for the
inhibition of basal FSH secretion into the culture medium
by FS-288 and FS-315 in the presence and absence of
heparan sulfate (10 μg/ml) were plotted, and revealed
that FS-288(ED50=5 ng/ml) was about 7 times more potent
than FS-315(ED50=35 ng/ml), and that heparan sulfate
reduced the inhibitory activity of FS-288 by about 50%,
whereas it had no effect on that of FS-315. These results
suggest that cell-associated FS-288 plays a more positive
role than FS-315 in controlling the action(s) of activin at
cell surfaces, and show the importance of the cell-surface
adhesiveness of FS to its role in controlling activin activity.
DEGRADATION OF ACTIVIN IN RAT CULTURED
GRANULOSA CELLS
We reported that activin stimulated the FSH-induced
differentiation of rat granulosa cells and enhanced the
induction by FSH of LH receptor expression in and
progesterone production by rat cultured granulosa cells
(27). As previously observed with cultured pituitary cells,
the presence of FS-288 markedly increased the affinity of
activin for heparan sulfate on granulosa cell surfaces,
whereas FS-315 did not enhance the activin binding to the
surfaces of these cells.
We demonstrated that rat cultured granulosa cells
produced FS protein and secreted it into the medium and
that FSH, but not LH, stimulated these events (71). Rat
granulosa cells were incubated with 125I-activin A (40 ng/
ml) in the absence or presence of FSH (100 ng/ml) or/
and heparin (10 mg/ml), and FSH stimulated activin A
Fig. 11. Uptake of 125I-activin A by rat pituitary cells. Rat pituitary
cells cultured in chamber slides were incubated with 125I-activin A
(40 ng/ml) in the absence (A) or presence (B) of FS-288 (200 ng/
ml), FS-315 (200 ng/ml) (C), FS-288 (200 ng/ml) and heparan
sulfate (10 μg/ml) (D) or FS-288 (200 ng/ml) and chloroquine (0.1
mM) (E) for 12 h at 37℃. After extensive washing, the cells were
fixed and subjected to autoradiography. Scale=50 μm.
Table 1. Effects of various lysosomal enzyme inhibitors on FS-288
-induced endocytotic degradation of activin A by rat pituitary cells
Rat pituitary cells (8 x 104 cells/well) cultured in 96-well plates
were incubated with 125I-activin A (40 ng/ml) and FS (200 ng/ml) in
the presence of various inhibitors for 24 h at 37℃, after which the
media were collected and 125I-activin A degradation was measured.
The activin degradation in the absence of inhibitors was designated
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degradation by about 2-fold compared with that in the
absence of FSH. This stimulatory effect was abolished by
the addition of heparin. Indeed, ligand blotting of the
culture medium demonstrated that both FS-315 and FS-
288 were produced and secreted into the medium in the
presence of FSH. Moreover, both FS-315 and FS-288
mRNA expressions were confirmed by reverse transcrip-
tion (RT)-PCR. These results indicate that, in response to
FSH, granulosa cells produce and secrete FS-288, which
itself adheres to the cells, and that the cell-associated FS-
288 can capture activin, leading to its endocytotic
degradation.
ROLE OF FOLLISTATIN IN NEURAL INDUCTION
IN XENOPUS EMBRYOS
Hemmati-Brivanlou et al. recently constructed a trun-
cated type II activin receptor and demonstrated that the
inhibition of the signal transduced by this receptor led to
neuralization in developing Xenopus embryos (72). They
proposed that FS RNA neuralized Xenopus ectodermal
explants directly in the absence of detectable mesoderm
(73). It has been argued that heparan sulfate proteogly-
cans are involved in mesoderm development and neural
induction in Xenopus embryos. Furuya et al . found that
heparan sulfate proteoglycans were expressed exclusively
in the animal hemisphere at the early gastrula stage of
Xenopus embryos and appeared predominantly on the
sheath of the neural tube, the notochord and epithelium
(74). In light of these recent findings, we speculated that
FS bound to heparan sulfate proteoglycans removes
activin signals from cell surfaces, as observed with rat
pituitary and ovarian granulosa cells, and we therefore
examined the affinity of FS for Xenopus heparan sulfate as
follows. Xenopus heparan sulfate was purified from
Xenopus embryos at the tadpole stage, labeled with tritium
acetate, and incubated with the required FS. The resulting
incubation mixture was filtered through nitrocellulose
membranes, which trapped heparan sulfate bound to FS.
FS-288 was found to bind to Xenopus heparan sulfate in a
dose-dependent manner, whereas FS-315
showed only slight affinity for it. When a
PCR was carried with a pair of suitable
primers to amplify the Xenopus short
form of FS, the short-form FS band did
not appear until the gastrula stage. Since
there is no information about the entire
cDNA sequence of Xenopus long-form FS,
its expression could not be detected.
Taken together, our preliminary results
strongly suggest that the short form of
Xenopus FS binds to embryonic cell
surfaces, and eliminates the activin signal
from the activin target cells, thereby
making them ready for neural induction.
Two organizer factors, chordin and
noggin, were recently found to be bone
morphogenetic factor (BMP)-binding
proteins (75, 76). These two factors
bind to BMP with high affinity and
abolish its activity by blocking binding to all cognate
surface receptors. Interestingly, both chordin and noggin
were observed to have affinity for heparin and heparan
sulfate, like FS. Therefore, BMP may bind to its target
cells via cell surface-bound chordin or noggin, followed by
endocytotic degradation, whereby BMP signaling may be
removed from its target cell surfaces.
CONCLUSION
FS binds stoichiometrically to activin to form an inactive
complex, which results in the blockade of various activin
bioactivities. However, the physiological significance of
this complex formation is not fully understood. In addi-
tion, little is known about the importance of the cell-
surface adhesiveness of FS regarding its role in
controlling activin bioavailability.
Heparan sulfate reduced the FSH-suppressing activity
of FS-288 more effectively than it did that of FS-315,
lending support to the hypothesis that FS isoforms have
different affinities for cell surfaces as well as differing
roles in the local modulation of activin function. Significant
binding of radioiodinated activin A to pituitary cell sur-
faces was observed only in the presence of FS. As
expected, FS-288 promoted this binding markedly and to a
greater extent than FS-315. When incubated with pituitary
cells in the presence of FS-288, activin A in the medium
appeared to be trapped by cell-associated FS-288. There-
fore, after being captured on the cell surface, activin
A may, together with FS-288 and proteoglycans, be
ingested by endocytotic vesicles, which ultimately fuse
with primary lysosomes and are degraded. Most of the
vesicle contents were found to be hydrolyzed into small
breakdown products and secreted to the exterior. There is
little doubt that activin A is broken down by such an endo-
cytotic degradation process, because various types of
inhibitor of each stage of this process significantly
blocked the activin A degradation : the inhibitors tested
included monensin, a proton ionophore and an endosome-
lysosome fusion inhibitor ; chloroquine, a lysosome
Fig.12. Regulatory mechanism of activin signal transduction by FS. Activin binds and
activates the transmembrane serine/threonine kinase of the type I/II receptor complex. FS
can neutralize activin bioactivity by interference with the binding of activin to activin type II
receptor. Cell surface-bound FS accelerates the endocytotic internalization of activin to its
degradation.
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function inhibitor, and several lysosomal protease inhibi-
tors. As was the case with radioiodinated activin A, the
proteolytic degradation of 125I-labeled FS-288 in pituitary
cells was observed. Taking these findings together, we
hypothesized that the endocytotic degradation of growth
factors via cell-surface heparan sulfate is necessary to
erase the growth factor signals from the surrounding cell
surfaces when they become excessive and thus useless. It
has been established that the binding of a signaling ligand
to its receptor stimulates a biological response and
triggers a sequence of events leading to cellular desensiti-
zation to the ligand in order to regulate the responsive-
ness of the target cell to the ligand. We propose that, in
addition to such receptor-mediated endocytosis, there
must be a scavenger mechanism for clearing signaling
molecules away from their target cell surfaces (Fig.12).
Our results demonstrated that cell-associated FS-288
(carboxy-terminal truncated FS) accelerates the endocy-
totic internalization of activin into rat pituitary cells, rat
granulosa cells and probably Xenopus animal hemisphere
cells, leading to its degradation by lysosomal enzymes.
Cell-associated FS therefore plays a role in the system
responsible for clearing the activin signal from cell
surfaces.
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